Analysts See $-0.02 EPS for BELLUS Health Inc. (BLU)

July 13, 2018 - By Michele Cranor

BELLUS Health Inc. (TSE:BLU) Logo

Analysts expect BELLUS Health Inc. (TSE:BLU) to report $-0.02 EPS on August, 8.After having $-0.02 EPS previously, BELLUS Health Inc.’s analysts see 0.00 % EPS growth. The stock increased 1.82% or $0.01 during the last trading session, reaching $0.56. About 81,905 shares traded. BELLUS Health Inc. (TSE:BLU) has 0.00% since July 13, 2017 and is . It has underperformed by 12.57% the S&P500.

BELLUS Health Inc., a biopharmaceutical company, engages in developing novel therapeutics for conditions with high unmet medical need. The company has market cap of $66.92 million. The Company’s pipeline of projects include BLU-5937, a small molecule antagonist of the P2X3 receptor for chronic cough; KIACTA, a novel drug candidate for the treatment of patients suffering from active pulmonary sarcoidosis, a rare fatal inflammatory condition that affects the lungs; and Shigamab for the treatment of hemolytic uremic syndrome caused by Shiga toxin-producing E. coli. It currently has negative earnings. The firm also has economic interests in various other partnered drug development projects, including AMO-01 for Fragile X Syndrome and ALZ-801 for APOE4 homozygous Alzheimer's disease.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.